PMGC Holdings Inc. Annual Report: A Simple Breakdown

I’ve put together this guide to help you understand how PMGC Holdings performed this year. My goal is to cut through the corporate jargon so you can decide if this company fits your portfolio.

1. What does this company do?

PMGC Holdings is a parent company that operates across four distinct areas:

• Northstrive Biosciences: A biotech firm developing pills to help people on weight-loss drugs (like Ozempic) maintain muscle mass while losing fat.
• Pacific Sun Packaging: A manufacturer of protective trays used to ship semiconductor chips and IT hardware.
• AGA Precision Systems: A machine shop that builds high-precision metal parts for aerospace and defense contractors.
• PMGC Capital: An investment arm that manages stakes in smaller growth companies to help fund the parent company.

2. Major Changes This Year

The company underwent a significant restructuring. In February 2025, they sold their skincare business for $2.5 million, exiting the cosmetics market. In July 2025, they acquired Pacific Sun Packaging and AGA Precision Systems for $18 million. This shifts their primary focus from consumer goods to industrial manufacturing, while maintaining their high-risk biotech arm.

3. The "Big Bet": Northstrive Biosciences

The company is betting its future on the weight-loss drug market. Their lead project, EL-22, is a pill designed to help users keep muscle mass. While early tests in mice were promising, the project is in the very early stages. They intend to request FDA permission to start human trials by the end of 2025.

The Reality Check: They are competing against industry giants with massive budgets and deep experience. PMGC currently lacks the cash and specialized infrastructure to run long, expensive clinical trials without finding a partner or raising additional capital.

4. Financial Health & Risks

The company’s latest report highlights a challenging financial situation:

• Cash Flow: The company lost $12.4 million this year and spends approximately $800,000 more than it generates every month. With less than $3 million in the bank, they rely on frequent capital raises.
• Biotech Exposure: The biotech segment has generated zero revenue. If the EL-22 project fails, the $5 million already invested in it will likely be lost.
• Stock Dilution: To fund acquisitions and daily operations, the company issued 40% more shares this year, which reduces the ownership percentage of existing shareholders.
• Listing Risks: Nasdaq has issued a warning regarding the company’s low stock price. Removal from the main exchange would reduce liquidity and likely lead to divestment by professional investors.
• Accounting Issues: Management has identified weak internal controls, noting a lack of sufficient staff to properly oversee the finances of their new manufacturing businesses.

5. The Bottom Line

This is a high-risk investment. While the company now generates $21 million in annual revenue from its manufacturing units, its long-term viability depends on a biotech project that is years away from potential profitability.

Given the high monthly burn rate, the constant issuance of new shares, the threat of delisting, and identified accounting weaknesses, this situation is highly volatile. This stock is only suitable for investors who are comfortable with the possibility of losing their entire investment. Before buying, consider whether you are comfortable with a company that is currently spending its cash reserves faster than it can generate revenue from its new industrial operations.